DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy Participants

Interventions: Drug: Semaglutide B, 1.34 mg/mL
Drug: Semaglutide B, 0.68 mg/mL

First Posted Date: 2023-01-18

Last Posted Date: 2024-10-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 20

Registration Number: NCT05689099

Locations: 🇺🇸
Altasciences Clinical LA, Inc., Cypress, California, United States

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)

Phase 3

Active, not recruiting

Conditions: Haemophilia A With Inhibitors
Haemophilia A

Interventions: Drug: Mim8

First Posted Date: 2023-01-17

Last Posted Date: 2025-05-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 451

Registration Number: NCT05685238

Locations: 🇬🇧
Evelina London Children's Hospital, London, United Kingdom
🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸
UC Denver Hemoph & Thrombo Ctr, Aurora, Colorado, United States

and more 115 locations

A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge

Phase 1

Completed

Conditions: Haemophilia A

Interventions: Drug: NNC0365-3769 (Mim8)

First Posted Date: 2023-01-12

Last Posted Date: 2024-10-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 205

Registration Number: NCT05681845

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Phase 3

Active, not recruiting

Conditions: Cardiovascular Disease

Interventions: Drug: Cagrilintide
Drug: Placebo
Drug: Semaglutide

First Posted Date: 2023-01-03

Last Posted Date: 2025-04-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7000

Registration Number: NCT05669755

Locations: 🇺🇸
Reyes Clinical Research, Inc, Miami, Florida, United States
🇫🇷
Centre Hospitalier Universitaire de Montpellier-Hopital Lapeyronie, Montpellier, France
🇫🇷
Aphp-Hopital La Pitie Salpetriere-2, Paris, France

and more 553 locations

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Phase 3

Completed

Conditions: Obesity
Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Semaglutide

First Posted Date: 2022-12-13

Last Posted Date: 2024-12-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 513

Registration Number: NCT05649137

Locations: 🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
John Muir Physicians Network, Concord, California, United States
🇺🇸
Velocity Clinical Research Westlake, Los Angeles, California, United States

and more 64 locations

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

Phase 3

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: Semaglutide

First Posted Date: 2022-12-12

Last Posted Date: 2025-04-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1407

Registration Number: NCT05646706

Locations: 🇧🇬
Acibadem City Clinic MHAT Tokuda Department of Endocrinology, Sofia, Bulgaria
🇧🇬
Medical centre "Medical arts medico-dental centre", Sofia, Bulgaria
🇧🇬
"Medical Center Medical Plus" Eood, Varna, Bulgaria

and more 97 locations

Obesity and Cardiovascular Diseases, Cross-sectional Study in Saudi Arabia

Completed

Conditions: Obesity and Cardiovascular Risk

Interventions: Other: No treatment given

First Posted Date: 2022-12-08

Last Posted Date: 2024-02-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1144

Registration Number: NCT05642533

Locations: 🇸🇦
King Abdul Aziz University Hospital - Jeddah, Jeddah, Saudi Arabia
🇸🇦
King Abdulaziz Hospital-Al Ahsa-National Guard, Al Ahsa, Saudi Arabia
🇸🇦
King Khaled University Hospital,King Saud Univ. Med. City, Riyadh, Saudi Arabia

and more 2 locations

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Phase 3

Recruiting

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Ziltivekimab

First Posted Date: 2022-12-05

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 5600

Registration Number: NCT05636176

Locations: 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇹🇭
Srinagarind Hospital, Khon Kaen, Thailand
🇹🇭
Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand

and more 878 locations

A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults

Phase 1

Active, not recruiting

Conditions: Healthy Volunteers

Interventions: Drug: NNC0582-0001
Drug: Placebo

First Posted Date: 2022-11-22

Last Posted Date: 2025-05-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 56

Registration Number: NCT05624580

Locations: 🇦🇹
Clinical Trials Unit / Center for Medical Research, Graz, Austria

An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct

Recruiting

Conditions: Haemophilia A

Interventions: Drug: Esperoct

First Posted Date: 2022-11-18

Last Posted Date: 2024-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 100

Registration Number: NCT05621746

Locations: 🇨🇦
Novo Nordisk Investigational Site, Hamilton, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy